1. Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis
- Author
-
Feng Wang, Limin Chen, Zhao Wang, Qiuyan Xu, He Huang, Hairong Wang, Xi Li, Mingjie Yu, Jiangen Chen, Fuhua Lin, Zhenghe Chen, Xiangheng Zhang, Qunying Yang, Yonggao Mou, and Chengcheng Guo
- Subjects
Non-small-cell lung cancer ,Brain metastasis ,Systemic inflammation score ,Neutrophil–lymphocyte ratio ,Albumin ,Prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Background Brain metastases (BM) from non-small-cell lung cancer (NSCLC) is the most common brain malignancy. Systemic inflammation biomarkers have recently been evaluated as prognosis indicators in several tumors. The combination of these markers has not been evaluated in NSCLC with BM yet. Here, we explored the predictive value of pretreatment inflammatory biomarkers and established a novel, clinically applicable prognostic index for NSCLC patients with BM. Methods A retrospective investigation of 951 NSCLC patients newly diagnosed with BM at Sun Yat-sen University Cancer Center was conducted. We randomly divided patients into a training cohort (n = 674) or validation cohort (n = 277). Receiver operating characteristic (ROC) curve analysis was carried out to obtain the optimal cut-off values of pretreatment systemic inflammatory indexes. The associations between serum biomarkers and overall survival (OS) were analyzed by Kaplan–Meier curves and Cox proportional models. The resulting prediction model has been externally verified through the validation cohort. Results The optimal cut-off value of the neutrophil–lymphocyte ratio (NLR) in predicting OS was 4.71, while the clinical standard of 40 mg/L was chosen as the optimal cut-off value of albumin. Univariate and multivariate analyses revealed that patients receiving local treatment, chemotherapy, a NLR
- Published
- 2022
- Full Text
- View/download PDF